Mission
Cannonball Kids’ cancer (CKc) Foundation’s mission is to fund innovative, accessible research for children fighting cancer to provide better treatments and quality of life, and to educate for change. Our vision is to create cures for all childhood cancers.
About CKc
Cannonball Kids’ cancer Foundation was founded in 2014 by Michael and Melissa Wiggins, parents of Cannon Wiggins, who was diagnosed with Stage IV high-risk neuroblastoma when he was just 20 months old. During Cannon’s treatment, they learned that very little time, effort and funding is devoted to finding cures for children’s cancer compared to adult cancers, and as a result, children are unnecessarily and unjustly lost. CKc aims to stop the tragic reality of children suffering and dying because of the lack of research in the world of children’s cancer treatments. CKc believes "Research is the Key" that will unlock a cure, and the foundation has now awarded $5.4 million in research grants, providing an option for over 1,000 children who were told they had "no more options". Most of those studies are first-of-their-kind and are dispersed throughout 35 U.S. states, D.C., Puerto Rico, Canada, Scotland and Switzerland.
Grant Programs
CKc offers two types of research grants: Clinical Trial and Young Investigator. The maximum award amounts and durations for the 2026 cycle are as follows:
• Young Investigator: $100,000 over 3 years
Funding Priorities
For the 2026 Grants Cycle, CKc will prioritize funding clinical trials and research that is nearing translation to a clinical trial. Grants funded by CKc must be innovative and provide better quality of life or symptom relief than current treatments.
For CKc, “innovation” means the invention or application of novel methods or treatments, specifically treatments that have fewer side-effects than standard care, increase a child’s quality of life, and/or create an option for care where there otherwise were few or none (either on primary diagnosis, relapse, or for recalcitrant cancers). Whenever possible, CKc will prioritize funding research with a focus on:
• cancers that are under-funded or under-researched.
• with a focus on patient populations who are traditionally underserved.
👉 Adult oncology or indirect pediatric relevance → low success probability
👉 ~94% of funded trials are first-of-their-kind
👉 Pure basic science without clinical trajectory is less competitive
Successful proposals demonstrate:
👉 “Better than standard of care” is a key requirement
👉 High unmet need = higher success probability
👉 CKc is strongly impact-driven, not publication-driven
👉 Collaboration improves feasibility and scalability
CKc prioritizes:
👉 Equity focus is a growing differentiator
👉 Overly ambitious proposals are commonly rejected
Highest impact factors:
Moderate predictors:
4. Better/less toxic treatments
5. Addressing unmet needs
6. Translational relevance
Supporting factors:
7. Investigator capability
8. Collaboration
9. Equity considerations
Compared to other pediatric cancer funders:
👉 Key evaluation question:
“Will this create a new treatment option for children—and can it reach patients quickly?”
• Applicants are limited to one Letter of Intent (LOI) per Principal Investigator (PI)
• PI must be employed by an academic or non-profit research institution or laboratory
• PI must be affiliated with a clinical department that supports the proposed research
• PI must have a medical doctoral degree: MD, DO, MD/PhD, or equivalent
• PI must demonstrate the potential to successfully conduct and complete the proposed clinical study and/or research
• The institution must have the infrastructure and resources necessary to support the proposed clinical study and/or research
Sponsor Institute/Organizations: Cannonball Kids' Cancer Foundation
Sponsor Type: Corporate/Non-Profit
Address: 1555 Howell Branch Rd., Suite C202 Winter Park, FL
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Jun 01, 2026
Sep 01, 2026
$100,000
Affiliation: Cannonball Kids' Cancer Foundation
Address: 1555 Howell Branch Rd., Suite C202 Winter Park, FL
Website URL: https://cannonballkidscancer.org/wp-content/uploads/2026/02/2026-CKc-Research-Grant-Guidelines-rev-Feb-2026.pdf
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.